

Table S1: Description of patients with major resistance mutations and INSTIs polymorphisms/substitutions at the pre-ART GRT: viroimmunological data and therapeutic management.

	NNRTIs, NRTIs and PIs Major Resistance Mutations/INSTIs Polymorphism or Substitutions	Baseline VL (copies/mL)	Baseline CD4 Count (cell/mm ³)	Initial ART	ART Change	Reason for Changing
Patient 1	K103N	3.873.430	354	TDF/FTC+DRV/r+RAL	Y	simplification
Patient 2	E138A	6.018	951	TDF/FTC+DRV/r+RAL	Y	simplification
Patient 3	G190A	225.709	605	TDF/FTC+DRV/r+RAL	Y	simplification
Patient 4	M41L; V106A	183.894	343	TDF/FTC+DRV/r+RAL	Y	simplification
Patient 5	E138A	108.779.000	341	TDF/FTC+DRV/r+RAL	Y	simplification
Patient 6	K103N	10.733	876	TDF/FTC+DTG	N	/
Patient 7	E138A	18.474.400	427	TDF/FTC+DTG	N	/
Patient 8	K103N	44612	359	TDF/FTC+DTG	N	/
Patient 9	E138G	332.394	697	TDF/FTC+DTG	N	/
Patient 10	E138A	165398	319	TDF/FTC+DRV/r+RAL	Y	simplification
Patient 11	M184V	160929	529	TDF/FTC+DRV/r+RAL	Y	simplification
Patient 12	E138A	44463	429	TDF/FTC+DRV/C+RAL	N	/
Patient 13	E138A	345518	155	TDF/FTC+DRV/C+RAL	N	/
Patient 14	T79A	38732	988	TDF/FTC+DRV/R+RAL	NA	
Patient 15	T79A	7378	625	TDF/FTC+DRV/C+RAL	Y	RAL withdrawal due to T97A

Notes: Abbreviations: NNRTIs, non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PIs protease inhibitors; INSTI integrase stand transfer inhibitors, VL viral load, ART antiretroviral regimen, TDF tenofovir disoproxil fumarate, FTC emtricitabine, DTG dolutegravir, RAL raltegravir, DRV/r darunavir/ritonavir, DRV/c darunavir/cobicistat, N no, Y yes.